Drug Information

Drug (ID: DG01756) and It's Reported Resistant Information

Name	Cediranib/PLX4720
Synonyms	Cediranib/PLX4720 Click to Show/Hide
Target	.	NOUNIPROTAC	[1]

Type(s) of Resistant Mechanism of This Drug

UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Click to Show/Hide the Resistance Disease of This Class

Melanoma [ICD-11: 2C30]

Click to Show/Hide

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
Unusual Activation of Pro-survival Pathway (UAPP)			Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF)				[1]
Molecule Alteration	Missense mutation		p.V600E (c.1799T>A)	Molecule Info
Sensitive Disease	Melanoma [ICD-11: 2C30.0]			Disease Info
Experimental Note	Identified from the Human Clinical Data
In Vitro Model	A375 cells	Skin	Homo sapiens (Human)	CVCL_0132
	WM451 cells	Skin	Homo sapiens (Human)	CVCL_6357
In Vivo Model	Nu/Nu(ISTMel1) mouse xenograft model; NSG (RPMI7951) female mouse xenograft model			Mus musculus
Experiment for Molecule Alteration	Western blotting analysis; Immunohistochemistry assay
Experiment for Drug Resistance	CellTiter-Glo assay

References

Ref 1	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentPLoS One. 2015 Oct 13;10(10):e0140310. doi: 10.1371/journal.pone.0140310. eCollection 2015.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.